Anti-CD19/BCMA CAR-T cells not checked

Hrain Biotechnology Co., Ltd.

FollowEvery change as it happens, and a Monday email
Stage
No active trials
 
Next date
None yet
 
Trials
0 active
1 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“Retroviral vector-transduced autologous T cells to express anti-CD19 and anti-BCMA CARs”In the company’s words, NCT03879382 on ClinicalTrials.gov
Tested for
POMES Syndrome, Relapsed and Refractory POMES Syndrome
Main trialPhase 1
“The goal of this clinical trial is to study the feasibility and efficacy of anti-CD19/BCMA bispecific chimeric antigen receptors (CARs) T cell therapy for relapsed and refractory POMES Syndrome.”In the company’s words, NCT03879382 on ClinicalTrials.gov

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1Unknown 30 Aug 2020 Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R POMES
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow Anti-CD19/BCMA CAR-T cells

Following is part of Solo: you see every change to Anti-CD19/BCMA CAR-T cells the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in